Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy
Author(s) -
Graham S. Ogg,
Xia Jin,
Sebastian Bonhoeffer,
Paul Moss,
Martin A. Nowak,
Simon Monard,
Jeremy Segal,
Yaming Cao,
Sarah Rowland–Jones,
Arlene Hurley,
Martin Markowitz,
David D. Ho,
Andrew J. McMichael,
Douglas F. Nixon
Publication year - 1999
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.73.1.797-800.1999
Subject(s) - ctl* , biology , viremia , cytotoxic t cell , effector , virology , immunology , antiretroviral therapy , human immunodeficiency virus (hiv) , virus , viral load , immune system , cd8 , in vitro , genetics
Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom